drugset
drugset / Trial / NCT07553663

Evaluating the Pharmacokinetics and Safety of Miricorilant

NCT07553663 ↗

Phase 1 Recruiting 15 enrolled Corcept Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Timeline

Start
2026-04-30
Primary completion
2026-10-30
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Miricorilant Small molecule 60 mg —

Indications

NAFLD1 metabolic dysfunction-associated steatohepatitis